Table 1 Characteristics of included studies
References | Perineural dexamethasone group | Intravenous dexamethasone group | Jada scores | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number | Age (years) | Female (n) | Weight (kg) | ASA physical status (I/II/III) | Methods | Number | Age (years) | Female (n) | Weight (kg) | ASA physical status (I/II/III) | Methods | ||
McHardy et al. [10] | 92 | 51.6 (18–73) | 25 | – | 25/49/18 | Interscalene block analgesia supplemented with perineural dexamethasone 4 mg | 90 | 52.8 (22–76) | 21 | – | 18/57/15 | Interscalene block analgesia supplemented with intravenous dexamethasone 4 mg | 5 |
Kahn et al. [12] | 63 | 50 ± 14 | 26 | – | 22/38/3 | Interscalene block supplemented with perineural dexamethasone 1 mg | 62 | 47 ± 15 | 23 | – | 26/33/3 | Interscalene block analgesia supplemented with intravenous dexamethasone 1 mg | 5 |
Holland et al. [13] | 70 | 54 ± 12 | 21 | 87 ± 16 | 24/40/6 | Interscalene block analgesia supplemented with perineural dexamethasone 4 mg | 69 | 53 ± 14 | 16 | 89 ± 17 | 21/44/5 | Interscalene block analgesia supplemented with intravenous dexamethasone 4 mg | 4 |
Sakae et al. [19] | 20 | 53.2 ± 9.8 | 8 | 63.2 ± 5.1 | 9/11/0 | Interscalene block analgesia supplemented with perineural dexamethasone 4 mg | 20 | 52.1 ± 12.3 | 6 | 65.3 ± 4.2 | 8/12/0 | Interscalene block analgesia supplemented with intravenous dexamethasone 4 mg | 3 |
Chun et al. [20] | 50 | 50.8 ± 17.5 | 17 | 69.6 ± 12.9 | 24/26/0 | Interscalene block analgesia supplemented with perineural dexamethasone 5 mg | 49 | 53.0 ± 14.2 | 15 | 68.0 ± 11.6 | 17/32/0 | Interscalene block analgesia supplemented with intravenous dexamethasone 5 mg | 4 |